Vaxxas Awarded US$5 million [AU$7.5 million] Grant for Clinical Study of Measles and Rubella Vaccination using Vaxxas’ High Density Micro-Array Patch
Funding Accelerates Vaxxas’ Clinical Pipeline of Innovative Vaccines CAMBRIDGE, Mass. & BRISBANE, Australia--(BUSINESS WIRE)--Vaxxas, a biotechnology company commercializing a novel...






